First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1 ...
IBI363 in combination with chemotherapy demonstrated encouraging efficacy signals and manageable safety in the first-line ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results